Abnormal psychology

New Report From Vista Research Group Shows Pandemic Caused 18% More People to Seek Addiction Treatment in 2021

Retrieved on: 
Tuesday, June 29, 2021

ANNAPOLIS, Md., June 29, 2021 /PRNewswire-PRWeb/ --A new report issued today by Vista Research Group, Inc. reveals that the stress of the pandemic caused 18% more people to need treatment for alcohol or drug addiction in the first quarter of 2021 compared to 2020.

Key Points: 
  • ANNAPOLIS, Md., June 29, 2021 /PRNewswire-PRWeb/ --A new report issued today by Vista Research Group, Inc. reveals that the stress of the pandemic caused 18% more people to need treatment for alcohol or drug addiction in the first quarter of 2021 compared to 2020.
  • The comprehensive State of Addiction Treatment 2021 report includes detailed information on the impact of the pandemic on 13,077 rehab patients and details how the pandemic affected regulatory, marketing, payer and merger & acquisition activity in the industry.
  • The biggest increase was among individuals entering treatment for the first time for alcohol use disorder, a group which grew from 19% of all patients in addiction treatment between 2016-2019 to 26% in the first quarter of 2021.
  • Unfortunately, less than 1% of addiction treatment centers invest in following up with patients post-treatment.

Signant Health Announces Launch of eCOA Acceleration Program & Remote Assessment Capabilities for CNS Studies

Retrieved on: 
Tuesday, June 29, 2021

Developed and validated with client feedback for a series of CNS studies, the program builds on Signant's rich, 20-year heritage in evidence generation for neurology research, including the first-ever use of eCOA in an Alzheimer's disease trial.

Key Points: 
  • Developed and validated with client feedback for a series of CNS studies, the program builds on Signant's rich, 20-year heritage in evidence generation for neurology research, including the first-ever use of eCOA in an Alzheimer's disease trial.
  • While validated in CNS studies, the acceleration program can be applied to any therapeutic area to maximize efficiency in study startup processes for traditional, hybrid, or decentralized trials.
  • At the core of the program is the creation and maintenance of a library of electronic clinician-rated outcome assessments that have undergone Signant's robust equivalence testing and clinical user acceptance testing processes.
  • To maintain the highest quality standards for complex clinician-reported outcomes, the program includes two crucial considerations.

Signant Health Announces Launch of eCOA Acceleration Program & Remote Assessment Capabilities for CNS Studies

Retrieved on: 
Tuesday, June 29, 2021

Developed and validated with client feedback for a series of CNS studies, the program builds on Signant's rich, 20-year heritage in evidence generation for neurology research, including the first-ever use of eCOA in an Alzheimer's disease trial.

Key Points: 
  • Developed and validated with client feedback for a series of CNS studies, the program builds on Signant's rich, 20-year heritage in evidence generation for neurology research, including the first-ever use of eCOA in an Alzheimer's disease trial.
  • While validated in CNS studies, the acceleration program can be applied to any therapeutic area to maximize efficiency in study startup processes for traditional, hybrid, or decentralized trials.
  • At the core of the program is the creation and maintenance of a library of electronic clinician-rated outcome assessments that have undergone Signant's robust equivalence testing and clinical user acceptance testing processes.
  • To maintain the highest quality standards for complex clinician-reported outcomes, the program includes two crucial considerations.

Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities [NCES] to Treat a Broad Range of Addiction Indications

Retrieved on: 
Monday, June 28, 2021

Broadening of Intellectual Property Portfolio for These Two NCES Clearly Defines Development Pathway for the Next Generation of Psychedelic Medicines to Treat Addiction

Key Points: 
  • The development candidates, AWKN001 and AWKN002, demonstrate a significant expansion and step forward in Awakn's drug discovery R&D activities with a focus on Addiction.
  • These improved candidates will enable us to treat more patients at a reduced cost and with the potential to increase both efficacy and the range of disorders we can treat.
  • Anthony Tennyson, Awakn's CEO commented, "Our ambition is to fully integrate effective psychedelic-based treatment into mainstream healthcare to better treat addiction.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction.

Statement from the Chief Public Health Officer of Canada on June 27, 2021

Retrieved on: 
Sunday, June 27, 2021

In the context of the COVID-19 pandemic, increased stressors and heightened risks have made many frontline and health workers susceptible to trauma and posttraumatic stress.

Key Points: 
  • In the context of the COVID-19 pandemic, increased stressors and heightened risks have made many frontline and health workers susceptible to trauma and posttraumatic stress.
  • A recent survey conducted by the Public Health Agency of Canada and Statistics Canada showed that 6% of Canadian adults reported moderate to severe symptoms of PTSD.
  • If you need support for your mental health or substance use, you can visit Wellness Together Canada for free help and resources.
  • However, we know that vaccination,in combination with public health and individual measures, are working to reduce spread of COVID-19.

Greenbrook TMS Withdraws Public Offering of Common Shares

Retrieved on: 
Friday, June 25, 2021

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company) today announced that it has elected to withdraw its previously announced public offering of common shares (the Offering).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company) today announced that it has elected to withdraw its previously announced public offering of common shares (the Offering).
  • Operating through 129 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 620,000 TMS treatments to over 17,000 patients struggling with depression.

Pelorus Elder & Behavioral Health Opens Pelorus TMS Therapy Center in Raritan, NJ

Retrieved on: 
Friday, June 25, 2021

Pelorus uses NeuroStar TMS Machines leveraging magnetic fields to stimulate the regions of the brain associated with depression.

Key Points: 
  • Pelorus uses NeuroStar TMS Machines leveraging magnetic fields to stimulate the regions of the brain associated with depression.
  • NeuroStar TMS treatment shows beneficial outcomes for patients that have yet to find a successful treatment for depression.
  • If you or a loved one has been struggling with treatment resistant depression, schedule a consultation or an appointment with Pelorus TMS.
  • Call today at 973-295-6335 or check out the Pelorus website to see if NeuroStar TMS Therapy may be the right fit for you.

Worldwide Depression Drugs Industry to 2026 - Featuring AstraZeneca, Novartis and Bristol-Myers Squibb Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021

The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global depression drugs market reached a value of US$ 12.7 Billion in 2020.
  • Looking forward, the global depression drugs market is expected to grow at a CAGR of around 3% during the forecast period (2021-2026).
  • The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth.

22KILL Expands Services, Launches Under New Name — One Tribe Foundation — to Address Growing Need for Mental Health Resources

Retrieved on: 
Wednesday, June 23, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210623005685/en/
    Jacob Schick, CEO of 22KILL, announces organization's name change to One Tribe Foundation to expand mental wellness services to include veterans, first responders and health care workers.
  • (Photo: Business Wire)
    One Tribe Foundation, formerly known as 22KILL, is launching new programs, services and facilities to address todays growing mental health issues including depression, anxiety, post-traumatic stress disorder (PTSD), and suicide.
  • During the same period in North Texas, One Tribe Foundation (operating as 22KILL) provided 7,082 counseling sessions.
  • The One Tribe Foundation launch celebration event was hosted by Natalie Woods Stanyer, TV personality and former Dallas Cowboys Cheerleader.

PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Retrieved on: 
Wednesday, June 23, 2021

Based on results from the Phase 1b trial in healthy elderly volunteers, Karuna plans to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022.

Key Points: 
  • Based on results from the Phase 1b trial in healthy elderly volunteers, Karuna plans to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022.
  • 23, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers.
  • Based on results from the Phase 1b trial in healthy elderly volunteers, the Company plans to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022.
  • The placebo-controlled, inpatient Phase 1b dose-ranging trial consisted of three cohorts, each enrolling 16 healthy elderly volunteers, randomized 3:1 to receive KarXT or placebo.